TG Therapeutics Banner Image

TG Therapeutics

  • Ticker TGTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
TG Therapeutics Logo Image
  • 11-50 Employees
  • Based in New York City, New York
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific andMore unique epitope on the CD20 antigen found on mature B-lymphocytes.
4.8 / 5.0 (118)

TG Therapeutics reports have an aggregate usefulness score of 4.8 based on 118 reviews.

TG Therapeutics

Most Recent Annual Report

TG Therapeutics
MOST RECENT 2022 Annual Report and Form 10K

TG Therapeutics does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

TG Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!